Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer.

4 Mar 2015

Chrono Therapeutics gets support to develop SmartStop device for smoking cessation

Chrono Therapeutics, a pioneer in digital drug products, today announced an investment by Rock Health, the leading seed fund in digital health, to support the advancement of Chrono's SmartStop programmable transdermal drug delivery system and real-time behavioral support program for smoking cessation.

3 Mar 2015

MIT researchers devise new way to make complex emulsions

MIT researchers have devised a new way to make complex liquid mixtures, known as emulsions, that could have many applications in drug delivery, sensing, cleaning up pollutants, and performing chemical reactions.

27 Feb 2015

Gates Foundation awards $2.5 million to support development of vaccine-filled microneedles

The Georgia Institute of Technology and Micron Biomedical have been awarded $2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization. The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio.

25 Feb 2015

Scientists use graphene to target, neutralise cancer stem cells

University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells.

25 Feb 2015

Love hormone has remarkable influence on the intoxicating effect of alcohol

Oxytocin, sometimes referred to as the 'love' or 'cuddle' hormone, has a legendary status in popular culture due to its vital role in social and sexual behaviour and long-term bonding.

24 Feb 2015

MIT chemical engineers develop new type of self-healing hydrogel

Scientists are interested in using gels to deliver drugs because they can be molded into specific shapes and designed to release their payload over a specified time period. However, current versions aren't always practical because must be implanted surgically.

20 Feb 2015

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center.

19 Feb 2015

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the all new InspiraChamber Anti-Static Valved Holding Chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory research and development company InspiRX Inc.

19 Feb 2015

Study findings could help scientists better design silicon materials to improve chemotherapy drug delivery

A team of Israeli and American researchers have found that silicon nanomaterials used for the localized delivery of chemotherapy drugs behave differently in cancerous tumors than they do in healthy tissues. The findings could help scientists better design such materials to facilitate the controlled and targeted release of the chemotherapy drugs to tumors.

16 Feb 2015

Biomedical use of gold nanotubes demonstrated in mouse model of human cancer

Scientists have shown that gold nanotubes have many applications in fighting cancer: internal nanoprobes for high-resolution imaging; drug delivery vehicles; and agents for destroying cancer cells.

13 Feb 2015

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Timing may be decisive when it comes to overcoming cancer's ability to evade treatment. By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models.

12 Feb 2015

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

New NIH grant to help restore function after spinal cord injury

Restoring function after spinal cord injury, which damages the connections that carry messages from the brain to the body and back, depends on forming new connections between the surviving nerve cells. While there are some delicate surgical techniques that reconnect the nerves, researchers are also looking at ways to restore the connections themselves at a cellular level.

10 Feb 2015

New stent for treating cardiovascular disease successfully implanted in patients

A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time.

10 Feb 2015

Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

With proposals ranging from innovative therapies to the development of unique organoid models of the brain, five scientists have been selected to receive the 2015 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health. The five scientists will each receive $500,000 per year for five years to support their research.

10 Feb 2015

Drug Delivery News and Research

Further Reading

Novogen's TRXE-009 therapy shows promise against brain cancer

Chrono Therapeutics gets support to develop SmartStop device for smoking cessation

MIT researchers devise new way to make complex emulsions

Gates Foundation awards $2.5 million to support development of vaccine-filled microneedles

Scientists use graphene to target, neutralise cancer stem cells

Love hormone has remarkable influence on the intoxicating effect of alcohol

MIT chemical engineers develop new type of self-healing hydrogel

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Study findings could help scientists better design silicon materials to improve chemotherapy drug delivery

Biomedical use of gold nanotubes demonstrated in mouse model of human cancer

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

New NIH grant to help restore function after spinal cord injury

New stent for treating cardiovascular disease successfully implanted in patients

Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

Cohera Medical gets FDA approval to distribute TissuGlu Surgical Adhesive in US

New findings could pave way to develop drug therapies for necrosis-related diseases

Chili peppers show promise as diet-based supplement

Researchers devise new technique to deliver cancer treatment

Must Know Trends for Drug Delivery Systems and the Crucial Role of Materials Testing eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo